Treatment for COVID-19 in High-Risk Adult Outpatients

Exclusion Criteria

• •Known hypersensitivity to HCQ or other 4-aminoquinoline compounds
• •Known hypersensitivity to azithromycin or other azalide or macrolide antibiotics
• •Currently hospitalized
• •Signs of respiratory distress prior to randomization, including respiratory rate \>24
• •Current medications include HCQ
• •Concomitant use of other anti-malarial treatment or chemoprophylaxis
• •History of retinopathy of any etiology
• •Psoriasis
• •Porphyria
• •Chronic kidney disease (Stage IV or receiving dialysis)
• •Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes \<1500) or thrombocytopenia (\<100 K)
• •Concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen
• •Known cirrhosis
• •Known personal or family history of long QT syndrome
• •History of coronary artery disease with a history of graft or stent
• •History of heart failure, Class 2 or greater using the New York Heart Association functional class
• •Taking medications associated with prolonged QT and known risk of torsades de points. These medications may include some antipsychotic and antidepressant medications. (Lopinavir-Ritonavir Platform)
• •Taking medications associated with prolonged QT such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial
• •Taking warfarin (Coumadin or Jantoven)
• •Known history of glucose-6-phosphate-dehydrogenase deficiency
• •History of myasthenia gravis